Suppression of tissue inhibitors of metalloproteinases may reverse severe pulmonary arterial hypertension

References

• Zhao YY, Malik AB. A novel insight into the mechanism of pulmonary hypertension involving caveolin-1 deficiency and endothelial nitric oxide synthase activation. Trends Cardiovasc Med. 2009;19:238–42.
   PubMed Web of Science ®Google Scholar
• Rabinovitch M, Bothwell T, Hayakawa BN, Williams WG, Trusler GA, Rowe RD, . Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension. A correlation of light with scanning electron microscopy and transmission electron microscopy. Lab Invest. 1986;55:632–53.
   PubMed Web of Science ®Google Scholar
• Frisdal E, Gest V, Vieillard-Baron A, Levame M, Lepetit H, Eddahibi S, . Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur Respir J. 2001;18:838–45.
   PubMed Web of Science ®Google Scholar
• Lepetit H, Eddahibi S, Fadel E, Frisdal E, Munaut C, Noel A, . Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J. 2005;25:834–42.
   PubMed Web of Science ®Google Scholar
• Prabha M, Jin HF, Tian Y, Tang CS, Du JB. Mechanisms responsible for pulmonary hypertension. Chin Med J. 2008;121:2604–9.
   Google Scholar
• Thakker-Varia S, Tozzi CA, Poiani GJ, Babiarz JP, Tatem L, Wilson FJ, . Expression of matrix-degrading enzymes in pulmonary vascular remodeling in the rat. Am J Physiol Lung Cell Mol Physiol. 1998;275:398–406.
   Google Scholar
• Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol. 2008;75:346–59.
   PubMed Web of Science ®Google Scholar
• Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006; 69:562–73.
   PubMed Web of Science ®Google Scholar
• McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol. 2001;13:534–40.
   PubMed Web of Science ®Google Scholar
• Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000;1477:267–83.
   PubMed Web of Science ®Google Scholar
• Vieillard-Baron A, Frisdal E, Raffestin B, Baker AH, Eddahibi S, Adnot S, . Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer limits monocrotaline-induced pulmonary vascular remodeling in rats. Hum Gene Ther. 2003; 14:861–9.
   PubMed Web of Science ®Google Scholar
• Cowan KN, Jones PL, Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest. 2000;105:21–34.
   PubMed Web of Science ®Google Scholar
• Vieillard-Baron A, Frisdal E, Eddahibi S, Deprez I, Baker AH, Newby AC, . Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer or doxycycline aggravates pulmonary hypertension in rats. Circ Res. 2000;87:418–25.
   PubMed Web of Science ®Google Scholar
• Junbao D, Hui Y, Bing W, Jian L, Jianguang Q, Chaoshu T. Effect of l-arginine on collagen of high flow-induced pulmonary arterial remodeling. Circ J. 2005;69:603–8.
   Google Scholar
• Higuchi M, Yasuda O, Kawamoto H, Yotsui T, Baba Y, Ozaki T, . Tissue inhibitor of metalloproteinase-3 deficiency inhibits blood pressure elevation and myocardial microvascular remodeling induced by chronic administration of Nomega-nitro-l-arginine methyl ester in mice. Hypertens Res. 2007; 30:563–71.
   Google Scholar
• Silence J, Collen D, Lijnen HR. Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene. Circ Res. 2002;90:897–903.
   PubMed Web of Science ®Google Scholar
• Lemaitre V, Soloway PD, D'Armiento J. Increased medial degradation with pseudo-aneurysm formation in apolipoprotein E-knockout mice deficient in tissue inhibitor of metalloproteinases-1. Circulation. 2003;107:333–8.
   PubMed Web of Science ®Google Scholar
• Chen P, Farivar AS, Mulligan MS, Madtes DK. Tissue inhibitor of metalloproteinase-1 deficiency abrogates obliterative airway disease after heterotopic tracheal transplantation. Am J Respir Cell Mol Biol. 2006;34:464–72.
   PubMedGoogle Scholar
• Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol. 2001;13:555–62.
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal. 2008;1:re6.
   PubMed Web of Science ®Google Scholar
• Tuder RM, Cool CD, Yeager M, Taraseviciene-Stewart L, Bull TM, Voelkel NF. The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med. 2001;22:405–18.
   PubMed Web of Science ®Google Scholar
• Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, . Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004; 43:13–24S.
   PubMed Web of Science ®Google Scholar
• Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, . Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348:593–600.
   PubMed Web of Science ®Google Scholar
• Akahane T, Akahane M, Shah A, Connor CM, Thorgeirsson UP. TIMP-1 inhibits microvascular endothelial cell migration by MMP-dependent and MMP-independent mechanisms. Exp Cell Res. 2004;301:158–67.
   PubMed Web of Science ®Google Scholar
• Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cells proliferation. J Cell Physiol. 1993;157:351–8.
   PubMed Web of Science ®Google Scholar
• Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, . TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell. 2003;114:171–80.
   PubMed Web of Science ®Google Scholar
• Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, . A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med. 2003; 9:407–15.
   PubMed Web of Science ®Google Scholar
• Zhen-Zhou C, Xiao-Dan J, Gui-Tao L, Jiang-Hua S, Ling-Hui L, Mou-Xuan D, . Functional and ultrastructural analysis of endothelial-like cells derived from bone marrow stromal cells. Cytotherapy. 2008;10:611–24.
   PubMed Web of Science ®Google Scholar
• Haack-Sorensen M, Bindslev L, Mortensen S, Friis T, Kastrup J. The influence of freezing and storage on the characteristics and functions of human mesenchymal stromal cells isolated for clinical use. Cytotherapy. 2007;9:328–37.
   PubMed Web of Science ®Google Scholar
• Szmitko PE, Fedak PW, Weisel RD, Stewart DJ, Kutryk MJ, Verma S. Endothelial progenitor cells: new hope for a broken heart. Circulation. 2003;107:3093–100.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, . Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999;5:434–8.
   PubMed Web of Science ®Google Scholar
• Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res. 2005;96:442–50.
   PubMed Web of Science ®Google Scholar
• Xia L, Fu GS, Yang JX, Zhang FR, Wang XX. Endothelial progenitor cells may inhibit apoptosis of pulmonary microvascular endothelial cells: new insights into cell therapy for pulmonary arterial hypertension. Cytotherapy. 2009;11: 492–502.
   PubMed Web of Science ®Google Scholar
• Mund JA, Ingram DA, Yoder MC, Case J. Endothelial progenitor cells and cardiovascular cell-based therapies. Cytotherapy. 2009;11:103–13.
   PubMed Web of Science ®Google Scholar
• Tondreau T, Meuleman N, Stamatopoulos B, De Bruyn C, Delforge A, Dejeneffe M, . In vitro study of matrix metalloproteinase/tissue inhibitor of metalloproteinase production by mesenchymal stromal cells in response to inflammatory cytokines: the role of their migration in injured tissues. Cytotherapy. 2009;11:559–69.
   PubMed Web of Science ®Google Scholar
• Huang PH, Chen YH, Wang CH, Chen JS, Tsai HY, Lin FY, . Matrix metalloproteinase-9 is essential for ischemia-induced neovascularization by modulating bone marrow-derived endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2009;29:1179–84.
   PubMed Web of Science ®Google Scholar